A retrospective study to evaluate the impact of proteinuria induced by Atezolizumab plus Bevacizumab on renal function and other renal-related adverse events in patients with unresectable hepatocellular carcinoma.

A retrospective study to evaluate the impact of proteinuria induced by Atezolizumab plus Bevacizumab on renal function and other renal-related adverse events in patients with unresectable hepatocellular carcinoma. - Atezolizumab plus Bevacizumab-Related Impact on Renal Function and Adverse Events Trial

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000050692

Enrollment

120

Registered

2023-03-31

Start date

2023-03-31

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hepatocellular carcinoma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1)Patients who were treated Atezo+Bev for unresectable hepatocellular carcinoma between September 25, 2020 and May 31, 2022. (2)Patients aged 18 years or older at the start of Atezo+Bev treatment (3)Patients who have not declared their refusal during the period of this study and the documents regarding the use of existing information described in the protocol posted on the website of the Department of Gastroenterology, Kindai University School of Medicine

Exclusion criteria

Exclusion criteria: (1)Patients with missing UPCR and eGFR data at baseline (2)Patients with all missing UPCR and eGFR data after starting Atezo+Bev treatment (3)Patients with Child-Pugh Classification Class C at the start of Atezo+Bev treatment (4)Patients deemed ineligible for this study by their physician

Design outcomes

Primary

Measure	Time frame
Correlation between change in UPCR (urine protein/creatinine ratio) and change in eGFR from baseline.	—

Secondary

Measure	Time frame
(1)Correlation between change in urine dipstick test and change in eGFR from baseline (2)Correlation of the score of UPCR / urine dipstick test and eGFR change at baseline (3)Correlation of coexistence/occurrence of proteinuria and eGFR change (4)Risk factors for renal function decline (5)Risk factors for proteinuria (6)Correlation between occurrence of adverse event and change in UPCR/ urine dipstick test (7)Correlation between UPCR and urine dipstick test	—

Measure

Time frame

(1)Correlation between change in urine dipstick test and change in eGFR from baseline (2)Correlation of the score of UPCR / urine dipstick test and eGFR change at baseline (3)Correlation of coexistence/occurrence of proteinuria and eGFR change (4)Risk factors for renal function decline (5)Risk factors for proteinuria (6)Correlation between occurrence of adverse event and change in UPCR/ urine dipstick test (7)Correlation between UPCR and urine dipstick test

—

Countries

Japan

Contacts

Public ContactKazuomi Ueshima

Kindai University Faculty of Medicine Department of Gastroenterology and Hepatology

kaz-ues@med.kindai.ac.jp072-366-0221

Outcome results